www.stiripesurse.ro/cancerul-de-prostata-o-amenint

Nearly 8,000 Romanian men are diagnosed with prostate cancer annually, making it the second most common cancer among men in Romania. Bayer emphasizes the importance of medical evaluations and PSA testing for early detection. GLOBOCAN 2024 estimates indicate that prostate cancer accounts for 14.9% of new cancer cases in Romanian men, with approximately 2,400 deaths each year. The MARIN project aims to screen over 23,000 men aged 50-70, particularly from vulnerable groups, offering free PSA tests and urological consultations. Early detection can improve treatment options, while ongoing research continues to enhance patient outcomes.